Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.37 CAD | +1.28% | +4.41% | +464.29% |
May. 22 | Medicenna to Present Clinical Update on MDNA11 ABILITY-1 Trial at Sachs Oncology Innovation Forum | MT |
May. 13 | Medicenna Says ABILITY-1 Abstract Withdrawn by ASCO Program Committee | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+464.29% | 128M | |
+66.72% | 62.86B | |
-1.08% | 41.38B | |
+45.66% | 40.38B | |
-8.93% | 27.64B | |
+13.54% | 26.46B | |
-22.96% | 18.9B | |
+3.96% | 12.67B | |
+23.72% | 12.27B | |
+27.65% | 12.07B |
- Stock Market
- Equities
- MDNA Stock
- News Medicenna Therapeutics Corp.
- Medicenna Says First Patient Dosed in ABILITY-1 Study of MDNA11 in Combination with Keytruda in Patients with Advanced Solid Tumors